NSTEMI part 2. Pharmacotherapy: antiplatelets, anticoagulants, other therapies

freecme000
Published on Dec 24, 2024
01:10 1-Other therapies
01:10 Î²-blocker: acute, long term, low EF, normal EF
10:14 ACE-I
13:21 Aldosterone antagonist
16:01 Entresto and SGLT-2 inhibitors
20:08 Summary slide

23:22 2-Antiplatelet therapy
23:22 Clopidogrel vs prasugrel vs ticagrelor: differences? which one to use? Factors to consider? Should we preload?
36:58 De-escalation from potent P2Y12 inhibitors DAPT to clopidogrel DAPT at 1 month
38:18 De-escalate to clopidogrel monotherapy at 1 month? Trials and guidelines
43:22 What is high ischemic risk? What is high bleeding risk?
46:50 De-escalate to ticagrelor monotherapy at 1 month? Trials
49:07 Patients who also require chronic anticoagulation

51:02 3-Anticoagulant therapy
52:07 UFH preferred to enoxaparin. Trials, guidelines
53:21 how to dose enoxaparin during cath and PCI- Disadvantages
57:54 Dose of UFH in ACS less than PE. Role of fondaparinux (59:35)
01:52:02 How to manage anticoagulation in ACS pre-cath and during cath in patients who are chronically taking warfarin or NOAC. Radial vs femoral

01:08:38 4-IV Glycoprotein IIb/III inhibitors (GPI) and IV Cangrelor
01:10:48 Cangrelor: when to use? It is not a bailout drug and has narrower indications than GPI
01:13:40 How to switch from cangrelor to oral P2Y12 antagonist